Exiqon to Acquire Oncotech Inc and Enter the Market for Cancer Molecular Diagnostics in 2008
News Nov 27, 2007
Exiqon A/S has announced that it has signed a binding Letter of Intent to acquire Oncotech Inc. through an all share transaction. As a result of the proposed transaction, a number of the goals set up during the IPO of Exiqon that occurred earlier this year will be realized sooner than originally anticipated and a significant step towards becoming a world leader within diagnostic products based on miRNA will have been achieved.
The proposed transaction will allow Exiqon and Oncotech through a combination of their resources to become a leading supplier of molecular diagnostic tests based on proprietary miRNA biomarkers. Combining the two companies will allow Oncotech to gain access to Exiqon’s superior LNA™-detection technologies and proprietary miRNA biomarkers and will allow Exiqon to master a number of challenges in building a platform for its future molecular diagnostic business.
Consequently, the proposed transaction will increase the likelihood of success and increase the speed in which new molecular diagnostic products can be marketed by Exiqon, the company says.
The first molecular diagnostic test based on miRNA biomarkers will be launched within 12 months following closing of the proposed transaction. More products will follow in the coming years. An ambitious product development plan has been developed by the management teams of both companies.
Oncotech will serve as the vehicle to market future molecular diagnostic products developed by the combined company providing a clear path to market for the future molecular diagnostic products based on Exiqon’s proprietary LNA™- technology and miRNA biomarkers.
The proposed transaction is expected to become final in January 2008 with effect as of January 1st, 2008 and does not change Exiqon’s financial expectations for 2007. The transaction will not compromise Exiqon’s financial goal of reaching profitability by 2011 with its current cash position and break even of the tools business by 2009.
Researchers Discover Mutation That Appears to Protect Against Multiple Aspects of Biological AgingNews
The first genetic mutation that appears to protect against multiple aspects of biological aging in humans has been discovered in an extended family of Old Order Amish living in the vicinity of Berne, Indiana, report Northwestern Medicine scientists.READ MORE
Defects in Cell’s ‘Waste Disposal System’ Linked to Parkinson’sNews
An international study has shed new light on the genetic factors associated with Parkinson’s disease, pointing at a group of lysosomal storage disorder genes as potential major contributors to the onset and progression of this common neurodegenerative disorder.READ MORE
Mouse Model Demonstrates Potential of New Autism DrugNews
Scientists have performed a successful test of a possible new drug in a mouse model of an autism disorder. The candidate drug, largely corrected electrical, behavioral and brain abnormalities in the mice.READ MORE